Consult your doctor or pharmacist for more information. Before having surgery, tell your doctor or dentist about all the products you use including prescription drugs , nonprescription drugs, and herbal products.

This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Caution is advised when using this drug in the elderly because they may be more sensitive to its side effects, especially stomach bleeding and kidney problems.

Children may be more sensitive to the side effects of this drug, especially serious liver problems. Caution is advised when this drug is used in children. Discuss the risks and benefits of treatment with your doctor. Before using this medication, women of childbearing age should talk with their doctor s about the benefits and risks such as miscarriage , trouble getting pregnant. Tell your doctor if you are pregnant or if you plan to become pregnant. During pregnancy , this medication should be used only when clearly needed.

This drug passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast -feeding. What should I know regarding pregnancy, nursing and administering Indomethacin Capsule, Extended Release to children or the elderly?

Interactions Drug interactions may change how your medications work or increase your risk for serious side effects.

This document does not contain all possible drug interactions. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Patients on long-term treatment with NSAIDs, including indomethacin, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients.

Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving indomethacin who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.

Preexisting Asthma Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal.

Since cross-reactivity, including bronchospasm, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, indomethacin should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.

Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Indomethacin, like other NSAIDs, can cause GI discomfort and, rarely, serious GI side effects, such as ulcers and bleeding, which may result in hospitalization and even death. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative signs or symptoms including epigastric pain, dyspepsia, melena, and hematemesis.

Risk of Ulceration, Bleeding, and Perforation. Although serious skin reactions may occur without warning, patients should be alert for the signs and symptoms of skin rash and blisters, fever, or other signs of hypersensitivity such as itching, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of rash and contact their physicians as soon as possible. Patients should promptly report signs or symptoms of unexplained weight gain or edema to their physicians.

Patients should be informed of the warning signs and symptoms of hepatotoxicity e. If these occur, patients should be instructed to stop therapy and seek immediate medical therapy. In late pregnancy, as with other NSAIDs, indomethacin should be avoided because it may cause premature closure of the ductus arteriosus. Indomethacin can reduce the antihypertensive effects of captopril and losartan.

In some patients with compromised renal function, the coadministration of an NSAID and an ACE inhibitor or an angiotensin II antagonist may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.

Aspirin When indomethacin is administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin is not altered. The clinical significance of this interaction is not known. The use of indomethacin in conjunction with aspirin or other salicylates is not recommended.

Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone. In a clinical study of the combined use of indomethacin and aspirin, the incidence of gastrointestinal side effects was significantly increased with combined therapy. In a study in normal volunteers, it was found that chronic concurrent administration of 3. Beta-Adrenoceptor Blocking Agents Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal anti-inflammatory drugs including indomethacin has been reported.

Therefore, when using these blocking agents to treat hypertension, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained. Cyclosporin Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.

NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored. Diflunisal In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin. A post-marketing study conducted in Poland using a non-US vaccination schedule 2, 3, 4, and 12 months of age evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment.

However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen. Major The chronic coadministration of systemic polymyxins may increase the risk of developing nephrotoxicity, even in patients who have normal renal function. Since Polymyxin B is eliminated by the kidney, coadministration with other potentially nephrotoxic drugs, including nonsteroidal antiinflammatory drugs NSAIDs , may theoretically increase serum concentrations of either drug.

Concomitant administration of drugs that undergo substantial renal clearance, such as nonsteroidal antiinflammatory drugs NSAIDs , may result in delayed clearance of pralatrexate. The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Prazosin: Major Probenecid reduces the clearance of indomethacin, and a lower dosage of indomethacin may be required to produce a therapeutic effect.

Major Due to the thrombocytopenic effects of procarbazine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents.

Moderate The concomitant administration of quinolones and nonsteroidal antiinflammatory drugs has been reported to increase the risk of CNS stimulation and convulsive seizures. Patients with CNS disorders or other risk factors that may predispose them to seizure development or patients taking drugs that lower the seizure threshold may not be appropriate candidates for NSAID usage if they are also taking a quinolone.

Selective serotonin reuptake inhibitors: Moderate Sincalide-induced gallbladder ejection fraction may be affected by indomethacin. False study results are possible in patients with drug-induced hyper- or hypo-responsiveness; thorough patient history is important in the interpretation of results.

Sodium Hyaluronate, Hyaluronic Acid: Moderate Increased bruising or bleeding at the injection site may occur when using hyaluronate sodium with nonsteroidal antiinflammatory drugs NSAIDs. Sodium picosulfate; Magnesium oxide; Anhydrous citric acid: Moderate Use caution when prescribing sodium picosulfate; magnesium oxide; anhydrous citric acid in patients taking concomitant medications that may affect renal function such as nonsteroidal anti-inflammatory drugs NSAIDs.

Patients should be monitored closely for bleeding. Moderate It is possible that additive nephrotoxicity may occur in patients who receive nonsteroidal anti-inflammatory drugs NSAIDs concurrently with other nephrotoxic agents, such as streptomycin. Major Avoid the concomitant use of sulfamethoxazole and indomethacin as coadministration may result in increased serum concentrations of sulfamethoxazole.

Coadministration may increase the risk of sulfamethoxazole toxicity. Minor Concurrent or sequential use of telavancin with drugs that inhibit renal prostaglandins such as nonsteroidal antiinflammatory drugs NSAIDS may lead to additive nephrotoxicity.

Closely monitor renal function and adjust telavancin doses based on calculated creatinine clearance. Moderate Drugs that alter renal function such as NSAIDs may alter telbivudine plasma concentrations because telbivudine is eliminated primarily by renal excretion. Monitor renal function before and during telbivudine treatment. Major Myelosuppression, primarily neutropenia and thrombocytopenia, is the dose-limiting toxicity of temozolomide. Due to the thrombocytopenic effects of temozolomide, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, ASA, strontium chloride, and thrombolytic agents.

Major Dose-limiting bone marrow suppression is the most significant toxicity associated with teniposide, and may include thrombocytopenia. Salicylates also displace protein-bound teniposide in fresh human serum to a small but significant extent. Because of the extremely high binding of teniposide to plasma proteins, these small decreases in binding could cause substantial increases in plasma free drug concentrations that could result in potentiation of teniposide toxicity, including bone marrow suppression.

Moderate Avoid administering tenofovir-containing medications concurrently with or recently after a nephrotoxic agent, such as high-dose or multiple nonsteroidal antiinflammatory drugs NSAIDs. If these drugs must be coadministered, carefully monitor the estimated creatinine clearance, serum phosphorus, urine glucose, and urine protein prior to, and periodically during, treatment.

Major Due to the thrombocytopenic effects of thioguanine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents.

Major Thiotepa is highly toxic to the hematopoietic system, and causes thrombocytopenia, leukopenia, and anemia. The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Ticarcillin: The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Timolol: The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Tobacco: Moderate It is possible that additive nephrotoxicity may occur in patients who receive nonsteroidal anti-inflammatory drugs NSAIDs concurrently with other nephrotoxic agents, such as tobramycin.

Major The tositumomab therapeutic regimen frequently causes severe and prolonged thrombocytopenia. Moderate Platelet aggregation may be impaired by trazodone due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e.

Patients should be instructed to monitor for signs and symptoms of bleeding while taking trazodone concurrently with medications that impair platelet function and to promptly report any bleeding events to the practitioner. Minor Concurrent use of nephrotoxic agents, such as NSAIDs, with valganciclovir should be done cautiously to avoid additive nephrotoxicity.

Valproic Acid, Divalproex Sodium: Moderate Due to the high protein binding of NSAIDs, they could displace other highly protein-bound drugs such as valproic acid, divalproex sodium from albumin binding sites in the blood leading to an increase in valproic acid free drug concentrations. In such cases, a patient may experience valproic acid toxicity even if the total drug concentration is within the therapeutic range. Minor It is possible that additive nephrotoxicity may occur in patients who receive NSAIDs concurrently with other nephrotoxic agents, including vancomycin.

Major Concomitant use of vemurafenib and indomethacin may result in increased indomethacin concentrations. Patients should be monitored for toxicity. Moderate Platelet aggregation may be impaired by venlafaxine due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e.

Moderate Platelet aggregation may be impaired by vilazodone due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e.

Patients should be instructed to monitor for signs and symptoms of bleeding while taking vilazodone concurrently with NSAIDs and to promptly report any bleeding events to the practitioner. Major Due to the thrombocytopenic effects of vinblastine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents. Major An increased risk of bleeding may occur when NSAIDs, such as vincristine, are used with agents that cause clinically significant thrombocytopenia, such as myelosuppressive antineoplastic agents.

Major Due to the thrombocytopenic effects of vinorelbine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants, NSAIDs, platelet inhibitors, including aspirin, strontium chloride, and thrombolytic agents. The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase in occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Voriconazole: The clinical significance of this potential interaction is unknown.

Moderate Platelet aggregation may be impaired by vortioxetine due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e.

Bleeding events related to drugs that inhibit serotonin reuptake have ranged from ecchymosis to life-threatening hemorrhages. Patients should be instructed to monitor for signs and symptoms of bleeding while taking vortioxetine concurrently with medications which impair platelet function and to promptly report any bleeding events to the practitioner.

Moderate Monitor patients for signs or symptoms of bleeding during concurrent use of warfarin and nonsteroidal antiinflammatory drugs NSAIDs. If signs or symptoms of bleeding occur, promptly evaluate and treat. NSAIDs inhibit platelet aggregation and may prolong bleeding time in some patients. Of note, intravenous indomethacin is used therapeutically short-term in neonates, including premature neonates, at doses significantly higher than those that would be delivered via breast milk.

Alternative analgesic and antiinflammatory drugs considered to be usually compatible with breast-feeding include acetaminophen, ibuprofen, naproxen, and piroxicam. Injectable indomethacin is only indicated for use in neonates and should not be used in breast-feeding mothers. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.

If a breast-feeding infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA. The enzymes COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin G2 PGG2 , the first step of the synthesis prostaglandins and thromboxanes that are involved in rapid physiological responses.

COX-1 is constitutively expressed in almost all tissues, while COX-2 appears to only be constitutively expressed in the brain, kidney, bones, reproductive organs, and some neoplasms e. COX-1 is responsible for prostaglandin synthesis in response to stimulation by circulating hormones, as well as maintenance of normal renal function, gastric mucosal integrity, and hemostasis. However, COX-2 is inducible in many cells in response to certain mediators of inflammation e. The anti-inflammatory mechanism of indomethacin is due to decreased prostaglandin synthesis via inhibition of COX-1 and COX It appears that the anti-inflammatory effects may be primarily due to inhibition of the COX-2 isoenzyme.

However, COX-1 is expressed at some sites of inflammation. COX-1 is expressed in the joints of rheumatoid arthritis or osteoarthritis patients, especially the synovial lining, and it is the primary enzyme of prostaglandin synthesis in human bursitis. Indomethacin is effective in cases where inflammation has caused sensitivity of pain receptors hyperalgesia. It appears prostaglandins, specifically prostaglandins E and F, are responsible for sensitizing the pain receptors; therefore, NSAIDs have an indirect analgesic effect by inhibiting the production of further prostaglandins and does not directly affect hyperalgesia or the pain threshold.

Indomethacin promotes a return to a normal body temperature set point in the hypothalamus by suppressing the synthesis of prostaglandins, specifically PGE2, in circumventricular organs in and near the hypothalamus. Lab tests, including kidney function, complete blood cell counts, and blood pressure, may be done to monitor your progress or to check for side effects.

Be sure to keep all doctor and lab appointments. Use Indomethacin Capsules with caution in the ELDERLY; they may be more sensitive to its effects, including stomach bleeding, kidney problems, confusion, or mental changes. Indomethacin Capsules may harm the fetus.

Do not use it during the last 3 months of pregnancy. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Indomethacin Capsules while you are pregnant.

Indomethacin Capsules are found in breast milk. Do not breast-feed while you are taking Indomethacin Capsules. Possible side effects of Indomethacin Capsules: All medicines may cause side effects, but many people have no, or minor, side effects. Constipation ; diarrhea; dizziness; drowsiness; gas; headache; heartburn; nausea; stomach upset. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors.

Do not start using a new medication without telling your doctor. Where can I get more information? Your pharmacist can provide more information about indomethacin. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. Drug information contained herein may be time sensitive.

Indometacin

Among NSAIDs, indomethacin, naproxen, and piroxicam may have the greatest pressor effect, while the effects of sulindac and nabumetone may be significantly less. Storage Store at room medicine away from medicine and moisture. Monitor medicine Indomethacin Anti-Inflammatory Agents: However, even short-term therapy is not without risk. Elimination from 75mg plasma seems to be biphasic, yielding a half-life of about 1 hour indomethacin the first indomethacin and between 2. These laboratory abnormalities may progress, may remain unchanged or may be transient with continuing therapy. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. For patients taking lithium e. Indomethacin has been shown to be an effective anti-inflammatory agent, appropriate for long-term use in rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis. This risk may indomethacin with duration of use, indomethacin er 75mg medicine. Fortunately, my ulcer was not bleeding and the treatment is pretty medicine. 75mg on these levels, the average concentration present in breast milk was estimated to 75mg 0. Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. Get medical help right away if you have any symptoms of liver damage, indomethacin er 75mg medicine, including: False-negative results in the dexamethasone suppression test DST in patients being treated with 75mg have been reported.

PDA (close with indomethacin; Open with Misoprostol)

Tags: flomax 350mg bustina cla 45 amg 0-100 mph order oxycodone overseas

© Copyright 2017 Indomethacin er 75mg medicine / Indomethacin Er.